n/a
Abstract Title:

Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response.

Abstract Source:

Pharmacol Res. 2022 Mar 31 ;179:106198. Epub 2022 Mar 31. PMID: 35367343

Abstract Author(s):

Xuan-Run Wang, Ze-Bo Jiang, Cong Xu, Wei-Yu Meng, Pei Liu, Yi-Zhong Zhang, Chun Xie, Jing-Yi Xu, Ya-Jia Xie, Tu-Liang Liang, Hao-Xin Yan, Xing-Xing Fan, Xiao-Jun Yao, Qi-Biao Wu, Elaine Lai-Han Leung

Article Affiliation:

Xuan-Run Wang

Abstract:

Despite recent advances in diagnosis and therapeutic strategies, treatment of non-small-cell lung cancer (NSCLC) remains unsatisfactory in terms of prognosis. Andrographolide (AD), a principal active component of Andrographis paniculata (Burm.f.) Nees, exerts anti-cancer therapeutic properties. AD has been used for centuries in China for clinical treatment of viral infections. However, the pharmacological biology of AD in NSCLC remains unknown. In this study, AD regulated autophagy and PD-L1 expression in NSCLC. Molecular dynamics simulations indicated that AD bound directly to signal transducer and activator of transcription-3 (STAT3) with high affinity. Proteomics analysis indicated that AD reduced the expression of tumour PD-L1 in NSCLC by suppressing JAK2/STAT3 signalling. AD modulated the P62-dependent selective autophagic degradation of PD-L1 by inhibiting STAT3 phosphorylation. In vivo study revealed that AD suppressed tumour growth in H1975 xenograft mice and Lewis lung carcinoma cell models, and better efficacy was obtained at higher concentrations. AD prolonged the survival time of the mice and enhanced the treatment efficacy of anti-PD-1 mAb immunotherapy by stimulating CD8T cell infiltration and function. This work elucidated the specific mechanism by which AD inhibited NSCLC. Treatment with the combination of AD and anti-PD-1 mAb immunotherapy could be a potential strategy for patients with NSCLC.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.